TNF and prion disease: The effects of systemic LPS treatment on CNS prion disease coincide with the enhanced abundance and inflammatory activation of the microglia, as well as elevated production of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6, and cytotoxic mediators such as nitric oxide [182,183,184].